Drug Report History #126791
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v13-FR | Version v2-FR | |
|---|---|---|
| Language | French | French |
| Date Updated (Changed) | Updated to: 2021-11-03 | Was: 2020-10-21 |
| Drug Identification Number | 02444623 | 02444623 |
| Brand name | STRENSIQ | STRENSIQ |
| Common or Proper name | ASFOTASE ALFA | ASFOTASE ALFA |
| Company Name | ALEXION PHARMA GMBH | ALEXION PHARMA GMBH |
| Ingredients | ASFOTASE ALFA | ASFOTASE ALFA |
| Strength(s) | 40MG | 40MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size (Changed) | Updated to: 2ML, 3ML | Was: 2ML |
| Additional packaging sizes | ||
| ATC code | A16AB | A16AB |
| ATC description | OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS | OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2021-03-01 | 2021-03-01 |
| Actual start date | ||
| Estimated end date (Changed) | Updated to: | Was: 2021-08-31 |
| Actual end date (Changed) | Updated to: 2021-10-28 | Was: |
| Shortage status (Changed) | Updated to: Resolved | Was: Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments (Changed) | Updated to: 28mg/0.7mL (40mg/mL) presentation | Was: |
| Health Canada comments |